Abstract | PURPOSE: METHODS: Thirty-four APS patients (14 arterial/ venous thrombosis, 16 pregnancy morbidity, and 4 both), 41 patients with SARD lacking clinical APS criteria but demonstrating positivity for anti-β2GPI (aβ2GPI) IgG, and 20 healthy subjects (HS) were tested for aPL to cardiolipin (aCL), phosphatidic acid, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol (aPG), phosphatidylinositol, phosphatidylserine, β2GPI, prothrombin, and annexin V by LIA. Samples were also tested for aCL, aβ2GPI, aβ2GPI-domain 1 (aD1), and aβ2GPI-domains 4-5 (aD4-5) by ELISA and for lupus anti- coagulant. RESULTS: Comparison of LIA with ELISA revealed a good agreement for the consensus criteria aPL aβ2GPI and aCL IgG (kappa = 0.69, 0.68, respectively) and a moderate agreement for IgM (kappa = 0.52, 0.49, respectively). Regarding ELISA, aD1/aD4-5 demonstrated the best performance of differentiating APS from asymptomatic SARD [area under the curve (AUC): 0.76]. aPG IgG had the best performance by LIA (AUC: 0.72) not significantly different from aD1/aD4-5. There was a good agreement for aPG IgG with aD1/aD4-5 (kappa = 0.71). CONCLUSIONS: aD1/aD4-5 (ELISA) and aPG IgG (LIA) differentiate APS from SARD patients. PG appears to interact with β2GPI of APS patients and exposes D1 thereof for disease-specific aPL binding in LIA.
|
Authors | Cecilia Nalli, Valentina Somma, Laura Andreoli, Thomas Büttner, Peter Schierack, Michael Mahler, Dirk Roggenbuck, Angela Tincani |
Journal | Auto- immunity highlights
(Auto Immun Highlights)
Vol. 9
Issue 1
Pg. 6
(May 29 2018)
ISSN: 2038-0305 [Print] England |
PMID | 29845583
(Publication Type: Journal Article)
|